Skip to main content
. 2016 Feb 4;7:10517. doi: 10.1038/ncomms10517

Figure 2. TFF2 status was associated with the expansion of IMC/MDSCs and development of colorectal cancer.

Figure 2

(a,b) DSS treatment results in splenomegaly (a) and accumulation of CD11b+Gr-1+ cells (b) in Tff2-null and wild-type mice, but not in CD2–Tff2 counterparts. Representative data from two independent experiments, 3–6 mice per group for each time point. NS, non-significant, *P<0.05, ***P<0.001, ****P<0.0001, analysis of variance (ANOVA) test following Sidak's multiple comparison test. (c) Highest accumulation of splenic CD11b+Gr-1+ cells in TFF2-null mice compare with wild-type and CD2–Tff2 mice 5 months after AOM/DSS treatment. Data shown are representative of at least five experiments, n=3–6 mice in each group, Sidak's multiple comparison test after ANOVA test (d) Representative colons of Tff2-null, wild-type and CD2–Tff2 mice 5 months after AOM/DSS treatment. (e) Tumour number was inversely related to Tff2 status. Data shown are representative of at least four experiments, n=3–6 mice in each group, *P<0.05, ****P<0.0001, Sidak's multiple comparison test after ANOVA test (f) Representative hematoxylin and eosin staining of colon from CD2–Tff2, wild-type and Tff2-null mice. Scale bars are 800 μm (left panels) and 160 μm (right panels). (g) Tff2-null mice show higher dysphasia score (**P=0.008, Kruskal–Wallis test) and dysplasia area (**P<0.01, Holm–Sidak's multiple comparison test after ANOVA test), n=5–10 mice in group, evaluation of AOM-DSS-treated (5 months) CD2–Tff2, wild-type and Tff2-null mice.